Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended September 30, 2006. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. A significant portion of the company's financial performance is driven by a joint venture with Merck & Co., Inc. regarding cholesterol-lowering products (VYTORIN and ZETIA), which is accounted for using the equity method.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Net Sales | $2,574 million | $7,944 million | $7,184 million |
| Net Income | $309 million | $940 million | $143 million |
| Net Income Available to Common Shareholders | $287 million | $875 million | $78 million |
| Diluted EPS | $0.19 | $0.59 | $0.05 |
| Operating Cash Flow | N/A | $1,515 million | $546 million |
| Cash and Cash Equivalents (End of Period) | $2,574 million | $2,574 million | $4,194 million |
| Total Debt (Short-term + Long-term) | $2,648 million | $2,648 million | N/A |
| Equity Income from Cholesterol Joint Venture | $390 million | $1,056 million | $605 million |
Note: Total Debt calculated as Short-term borrowings ($235M) + Long-term debt ($2,413M) as of Sep 30, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% in the third quarter and 11% year-to-date compared to 2005. Growth was driven primarily by Prescription Pharmaceuticals, specifically REMICADE (+34% Q3), NASONEX (+30% Q3), and TEMODAR (+18% Q3).
- Profitability Surge: Net income available to common shareholders increased dramatically from $43 million in Q3 2005 to $287 million in Q3 2006. Year-to-date income rose from $78 million to $875 million.
- Joint Venture Impact: Equity income from the Merck cholesterol joint venture increased 81% in Q3 and 75% year-to-date, reflecting strong sales of VYTORIN and ZETIA.
- Special Charges: Special charges decreased significantly year-over-year. Q3 2006 charges were $10 million (vs. $6 million in 2005), and nine-month charges were $90 million (vs. $292 million in 2005). The 2005 charges were heavily influenced by litigation reserves for the Massachusetts Investigation.
- Cash Flow: Operating cash flow for the nine months ended September 30, 2006, was $1.515 billion, a substantial increase from $546 million in the prior year period.
Guidance, Outlook, and Risks
- Manufacturing Streamlining: The company announced plans to close facilities in Manati, Puerto Rico, and reduce workforce in New Jersey and Puerto Rico, eliminating approximately 1,100 positions. Total expenses are expected to range from $240 million to $250 million, with anticipated annual savings of approximately $100 million starting in 2007.
- Legal Settlement: On August 29, 2006, the company reached an agreement to settle the Massachusetts Investigation for an aggregate amount of $435 million ($180 million criminal fine, $255 million civil resolution). This settlement is subject to court approval.
- Outlook: Management anticipates continued growth in the cholesterol franchise in 2007. However, sales of hepatitis C franchise products in Japan are expected to decline in late 2006 and 2007 due to moderating patient enrollments. R&D expenses are expected to increase faster than net sales in the fourth quarter of 2006.
- Regulatory Risks: The company remains subject to an FDA Consent Decree regarding Good Manufacturing Practices (cGMP) at facilities in New Jersey and Puerto Rico. While revalidation programs are complete, third-party certification is pending. Additionally, the company faces ongoing investigations and litigation regarding Average Wholesale Price (AWP) practices.
- Accounting Changes: The company adopted SFAS 123R (Share-Based Payment) effective January 1, 2006, resulting in a $22 million cumulative effect benefit to income in the first nine months of 2006.
Investor Verification Checklist
- Joint Venture Dependency: Verify the sustainability of the Merck joint venture income, which constitutes a major portion of net income, and monitor potential impacts from generic competition in the cholesterol market.
- Legal Settlement Finality: Confirm the court approval status of the $435 million Massachusetts Investigation settlement and monitor ongoing AWP investigations and litigation.
- Manufacturing Costs: Track the execution of the manufacturing streamlining plan to ensure the projected $100 million in annual savings are realized and that no additional asset impairments occur.
- Regulatory Compliance: Monitor the status of the FDA Consent Decree certification and any potential penalties or operational restrictions arising from pharmacovigilance inspections.
- Product Pipeline: Assess the progress of key R&D candidates (e.g., golimumab, Thrombin Receptor Antagonist) given the company's heavy reliance on new product development to offset patent expirations.